A COMPARATIVE CLINICAL STUDY OF VAMANA & VIRECHANA WITH AND WITHOUT SHILAJIT YOGA IN THE MANAGEMENT OF MADHUMEHA W.S.R. TO TYPE-2 DIABETES MELLITUS by Raju, *K.V.Narasimha & Shyam Sharma, Radhey
AYUSHDHARA            ISSN: 2393-9583 (P)/ 2393-9591 (O) 
 An International Journal of Research in AYUSH and Allied Systems 
AYUSHDHARA | July - August 2016 | Vol 3 | Issue 4  749 
 
     
 
 
  
A COMPARATIVE CLINICAL STUDY OF VAMANA & VIRECHANA WITH AND WITHOUT SHILAJIT 
YOGA IN THE MANAGEMENT OF MADHUMEHA W.S.R. TO TYPE-2 DIABETES MELLITUS 
K.V.Narasimha Raju1*, Radhey Shyam Sharma2 
*1Associate Professor, Dept. of Kayachikitsa & D.M.S., MJF Ay. College & Hospital, Chomu, Jaipur.  
2Vice-Chancellor, Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur.  
 
KEYWORDS: Madhumeha, 
Vamana, Virechana, Shilajit, 
Salasaradi gana, DM-II. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABSTRACT  
Diabetes Mellitus, a syndrome of disordered metabolism with multifactorial 
aetiology is characterized by chronic hyperglycaemia subsequently leading to 
long-term damage, dysfunction and multiple organ failure. Owing to the 
importance of disseminating the awareness, first National Ayurveda Day 
celebrated on 28th Oct. 2016, observed the theme as ‘Ayurveda for prevention 
and control of Diabetes. Madhumeha concedes 2 subtypes viz., Dhatukshayaja 
and Margavarodhaja. ‘Samshodhanam Akurvatam’ forms one of the important 
aetiological factors of Madhumeha which instigated in considering Panchakarma 
procedures of Vamana and Virechana karma for Shodhana particularly in 
Margavarodhaja madhumeha and, for a comprehensive management Shilajit 
Yoga is considered for Shamana therapy. Material and Methods: The study 
involved Group A (90 days): Vamana & Virechana (30 days) + Placebo (60 days). 
Group B (90 days): Vamana & Virechana (30 days) + Shilajit yoga (60 days). 
Dosage: 1 Cap. of 1000mg. Twice daily, Before food. Results: In placebo 
controlled Group-A, 6 (13.63%) got Controlled results, 10 (22.72%) got Marked 
Improvement, 24 (54.54%) got Moderate Improvement, 4 (9%) got Mild 
Improvement and in 4 patients there is No Change. In case of Drug trial (Shilajit 
Yoga) Group-B, 24 (50%) got Controlled results, 14 (29.1%) got Marked 
Improvement and 10 (20.8%) got Moderate Improvement. Discussion: Vamana 
acts on the basic pathology of Bahudravasleshma and Bahuabadhameda. Vamana 
and Virechana seems to reduce the insulin resistance, and Virechana must be 
increasing insulin secretion also. In contrast to Group A, ‘Shilajit yoga’ 
intervened in Group B appears to have substantial controlling effect on the blood 
sugar levels with its Extra pancreatic and Immunomodulatory effects, and 
probably through Pancreatotrophic action. Conclusion: The final result of the 
study supports the role of Shilajit followed by Shodana procedures as a safe and 
complete substitute to allopathic medication in the patients with an excess of 
about 50-100mg/dl of blood glucose levels above normal levels, in FBS and PPBS 
values.   
INTRODUCTION
 Diabetes Mellitus (DM), a silent 
epidemic and a potentially life threatening life style 
disorder, has always been invincible. DM, a syndrome of 
disordered metabolism with multifactorial aetiology is 
characterized by chronic hyperglycaemia with 
disturbances in carbohydrate, fat and protein 
metabolism resulting from the defects in Insulin, 
subsequently leading to long-term damage, dysfunction 
and multiple organ failure [1-3]. Of the two variants, DM 
Type-2 is responsible for 90-95% of Diabetic cases 
worldwide. Diabetes is one of the major causes of 
premature deaths worldwide and for every 10 seconds 
two individuals develop diabetes and one person dies 
from its complications. According to International 
Diabetes Federation (IDF) Report & Atlas 2015- there are 
415 million people with Diabetes around the world with 
69.1 million cases in India and every 6 seconds a person 
dies from Diabetes. This is estimated to rise to 642 
million by 2040 [4].  
The whole concept of DM is the reiteration of 
what is known as Madhumeha, a type of Vataja Prameha 
enunciated in Ayurvedic epistemology. Vataja Prameha is 
of 4 types viz., Majja meha, Ojo or Madhu meha, Vasa 
meha, and Lasika meha, all of which are Asadhya in 
nature. Madhumeha concedes 2 subtypes viz., 
Dhatukshayaja and Margavarodhaja. Dhatukshayaja 
Madhumeha is purely Vataja and Asadhya, which may be 
construed as the invincible DM Type-1. Margavarodhaja 
Madhumeha is of Kapha & Pitta related Vatadosha and is 
Kricchrasadhya, which is in clinical concordance with the 
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intractable DM Type-2. Vataja Pramehas are Asadhya, 
nevertheless, treatments are mentioned, which should be 
perceived as the interventions specified for 
Margavarodhaja Madhumeha, an exceptionally 
Kricchrasadhyaja Vataja Prameha. 
  Charakacharya elucidates the aetiopathogenesis 
of Madhumeha, where ‘Samshodhanam Akurvatam’ forms 
one of the important aetiological factors and vitiation of 
Kapha & Pitta along with other Dushyas form the core 
pathology of Margovarodhaja Madhumeha.[5].  
This overview on the disease is the impetus for 
present research work which considers Vamana & 
Virechana procedures to mitigate Kapha & Pitta 
respectively, and Shilajit Yoga, as explained in 
Chakradatta, [6] to subjugate the disease.  
As mentioned in the above reference, the 
intervention with Shilajit Yoga is strictly advised only 
after Samsodhanam i.e., Vamana & Virechana karma, 
which forms the principle criteria for planning the study.  
MATERIALS AND METHODS 
 This study was conducted under a strict protocol 
to prevent bias and to reduce the sources of error in the 
study. This Randomized Controlled clinical trial was 
conducted under the following methods: 
1. Sample Size:  
110 clinically diagnosed Madhumeha patients were 
divided randomly into two groups: 
Group A: This is ‘Placebo Control Group’: 54 patients 
were registered, 44 patients completed the trial while 10 
Patients Left Against Medical Advice (LAMA) 
Group B: This is ‘Experimental Group’: 56 patients 
were registered, 48 patients completed the trial while 08 
patients Left Against Medical Advice (LAMA). 
2. Source Of Subjects: Out-Patient Department and In-
patient Department of Panchakarma, National Institute 
of Ayurveda, Jaipur. 
3. Informed Consent: The study was explained clearly 
to the subjects and their signed, written (in patient’s 
language) informed consent was taken before starting 
the trial. 
4. Selection Criteria: A disease specific proforma was 
prepared and the observations were recorded after 
performing General, Systemic examinations. 
a. Inclusion Criteria: 
 Diagnosed Subjects with classical signs and 
symptoms of DM-Type 2 were included in the trial. 
 Subjects who were ready to give written informed 
consent. 
 Patients of age between 20-60 years.  
b. Exclusion Criteria: 
 Who were not ready to give informed consent. 
 Patients of DM- Type 1 
 Type-2 Diabetes patients on insulin therapy. 
 Genetic defects 
 Gestational diabetes 
 Diseases of Exocrinopathies. 
 Diabetes due to Endocrinopathies – Acromegaly, 
Cushing’s syndrome, Glucogonoma, 
Pheochromocytoma, Hyperthyroidism etc. 
 Drug or Chemical induced DM. 
 Diabetes due to infections – Congenital Rubella, 
CMV etc. 
 DM with Retinopathy, Nephropathy & previous H/O 
Coma.. 
 DM associated with genetic syndromes- Down’s 
syndrome, Turner’s syndrome, Klienfelter’s 
syndrome.  
 c. Discontinuation Criteria 
 Patients who constantly had hypoglycemic levels 
during Shodhana karma. 
 Patients who constantly had hyperglycemic levels 
during Shodhana karma. 
 Patients who couldn’t strictly follow Purvakarma 
(Snehapana) or Paschatkarma (Samsarjana krama). 
 Patients who developed complications. 
Assessment Criteria  
Subjective Parameters 
 Prabhuta Mutrata 
 Avila Mutrata 
 Nakta Mutrata 
 Pipasa 
 Swedaadhikyata 
 Kshudhadhikya 
 Atinidra 
 Sramaswasa  
 Mukhamadhurya 
 Vibandha  
 Daurbalya  
 Pipilika Sancharati 
 Hasta Pada Tala Daha 
 Kara-Pada Suptata 
Subjective Assessment 
The Gradational Assessment of Subjective 
Criteria were considered from -‘Gradation of Symptoms: 
Medovaha Srotas, Criteria for Assessment of Results for 
Madhumeha’, a Chapter from the book -‘Developing 
Guidelines for Clinical Research Methodology in 
Ayurveda’, IPGTR&A, Jamnagar, 2011, written by Prof. 
M.S. Baghel. The following criteria were considered for 
the present study: 
Prabhuta mutrata – Frequency of urine 
1. 3 – 6 times per day, rarely at night 0 
2. 6 – 9 times per day, 0 – 2 times per night 1 
3. 9 – 12 times per day, 2 – 4 times per night 2 
4. More than 12 times per day, more than 4 times per night 3 
Avila mutrata (Turbidity): News Paper Test 
1. Crystal clear fluid 0 
2. Faintly cloudy, smoky or hazy with slight turbidity. 1 
3. Turbidity clearly visible but newsprint easily read through test tube 2 
4. Newsprint not easily read through test tube 3 
5. Newsprint cannot be seen through test tube 4 
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Naktamutrata (nocturnal micturation) 
1. No nocturnal micturation 0 
2. 1 – 2 times passing of urine at night 1 
3. 2 – 4 times passing of urine at night. 2 
4. more than 4 times passing of urine at night 3 
Pipasadhikya (Increased Thirst) 
1. Feeling of thirst (7 – 9 times/24 hours) & relieved by drinking water  0 
2. Feeling of moderate thirst (>9 - 11 times/24 hours) & relieved by drinking water 1 
3. Feeling of excess thirst (>11 – 13 times/24 hours) not relieved by drinking water  2 
4. Feeling of sever thirst (>13 times) not relieved by drinking water  3 
Svedadhikya (Perspiration) 
1. Sweating after heavy work and fast movement or in hot weather   0 
2. Profuse sweating after moderate work and movement 1 
3. Sweating after little work and movement (stepping ladder etc.) 2 
4. Profuse sweating after little work and movement  3 
5. Sweating even at rest or in cold weather 4 
Kṣudhadhikya (Increased Appetite) (1 meal = about 350gm diet) 
1. As usual / routine 0 
2. Slightly increased (1 meal extra with routine diet) 1 
3. Moderately increased (2 meals extra with routine diet) 2 
4. Markedly increased (3 meals extra with routine diet) 3 
Atinidra / Nidradhikya (Increased Sleep) 
1. Normal & sound sleep for 6 – 8 hrs. /24 hrs. with feeling of lightness and 
relaxation in the body & mind  
0 
2. Sleep >8 -9 hrs. /24 hrs. with slight heaviness in the body. 1 
3. Sleep >9 - 10 hrs. /24 hrs. with heaviness in the body associated with Jrimbha 2 
4. Sleep >10 hrs. /24 hrs. with heaviness in the body associated with Jrimbha & 
Tandra 
3 
Sramasvasa (Dyspnoea) 
1. Dyspnoea after heavy work and walking 0 
2. Dyspnoea after moderate work and walking 1 
3. Dyspnoea after mild work 2 
4. Dyspnoea even at resting condition 3 
Mukhamadhurya / Madhurasyata (Sweetness in mouth) 
1. Absent 0 
2. Occasional 1 
3. Frequently 2 
4. Continuous 3 
Vibandha / Purishabadhata (Constipation) 
1. Stool passes as per normal schedule 0 
2. Passes stool with strain, sometimes takes purgative 1 
3. Passes stool after more than 24 hours, frequently takes purgative 2 
4. Passes stool after gap of one day, normal purgatives does not work 3 
Daurbalya (Weakness) 
1. Can do routine exercise/work  0 
2. Can do moderate exercise with hesitancy 1 
3. Can do mild exercise only, with difficulty 2 
4. Cannot do mild exercise too 3 
Hasta-Padatala daha 
1. No Daha  0 
2. Hasta-Pada-tala daha found occasionally, mild, bearable 1 
3. Hasta-Pada-tala daha continues but bearable & not severe 2 
4. Hasta-Pada-tala daha continues and severe & unbearable 3 
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Kara-Pada suptata 
1. No suptata  0 
2. Kara-Pada suptata intermittent 1 
3. Kara-Pada suptata continuous but bearable & not severe    2 
4. Kara-Pada suptata continuous and severe & Unbearable 3 
Pippalika-Sancharati (Tingling sensation) 
1. No tingling sensations 0 
2. Tingling sensation that is not continuous does not disturb routine activity 1 
3. Continuous tingling sensation does not disturb routine activity 2 
4. Severe continuous tingling sensation disturbs routine activity  3 
ii. Objective Parameters 
 Hematological – TLC, DLC, ESR, Hb% 
 Biochemistry – FBS, PPBS, Lipid profile, HbA1c 
 Urine examination – Routine, Microscopic, FUS, 
PPUS 
6. Study Type, Design & Duration 
 The study was an Interventional type and 
Randomized Placebo Controlled Trial and the total Trial 
period was 90 days with 30 days for Shodhana karma 
(Vamana & Virechana) and 60 days for Drug / Placebo 
administration in both the Groups. 
 Group A (90 days): Vamana & Virechana (30 days) 
+ Placebo (60 days). 
 Group B (90 days): Vamana & Virechana (30 days) 
+ Shilajit yoga (60 days). 
 Any ongoing treatment for T2DM in all the patients 
was withheld for 3days prior to implementation of 
the research plan. The blood sugar levels thus 
achieved were considered for before treatment 
data. 
 Vamana karma and Virechana karma will be 
performed once with proper Purvakarma and 
Paschatkarma.  
 Follow up was done after 15 days of trial period. 
7. Drug Review 
a. Drugs for Shodhana Karma 
 Vamana Drugs Virechana Drugs 
 Madanaphala 
 Yashtimadhu 
 Vacha 
 Saindhav Lavan 
 Madhu 
 Trivrit 
 Hareetaki 
 Aragwada 
 Sanaya  
 
b. Shamana Drug: ‘Shilajit Yoga’ (Ref: Su.Ch / Bh.R / 
Chakradatta) 
Shilajit Processing: Shuddha Suryatapi Shilajit was 
collected and subjected to 7 Bhavanas with Salasaradi 
gana dravya kashaya. Then it was dried and powdered. 
Dosage: 1 Cap. of 1000mg. Twice daily, Before food. 
Anupana: Salasaradi Gana Kashaya. 
Duration: 60 days. 
Table 1: Salasaradi Gana Dravya: (S.Su. 38/ 12-13) [7] 
Drugs 
1 Salasara  13 Ashana 
2 Ajakarna 14 Dhava 
3 Khadira 15 Arjuna 
4 Kaalaskanda 16 Taala 
5 Kramuka 17 Shaaka 
6 Bhurja 18 Kadara 
7 Meshashringi 19 Naktamaala 
8 Tinisha 20 Puteeka 
9 Chandana 21 Ashwakarna 
10 Kuchandana 22 Aguru 
11 Shimshapa 23 Kaaleeyakam 
12 Shireesha 
Out of the above listed drugs of Salasaradi Gana, 
the following drugs which were available in the market 
were procured and used for the preparation of Kashaya 
to be used for Bhavana of Shilajit and for dispensing to 
the trial patients in the form of Yavakuta churna to 
prepare Anupana. 
 Available Drugs 
(Salasaradi Gana) 
Useful part 
Khadira Resin  
Kramuka Fruit 
Meshasringi Leaves  
Sireesha Bark  
Arjuna Bark 
Karanja Seeds  
8. Follow Up Study 
 Patients were followed after 15 days of the trial 
period. 
 Laboratory investigation was repeated after 
complete treatment. 
 Improvement and other side effects were noted. 
Assessment of Overall Effect of the Therapy 
1) Control of the disease: improvement in FBS and 
PPBS by > 50 mg/dl or reaching normal range and 
sign- symptoms relieving completely. 
2) Marked Improvement: Relieved signs / symptoms 
and improved FBS and PPBS 26-50 mg/dl. 
3) Moderate Improvement: Moderately improved signs 
/ symptoms with an improvement of 10-25 mg/dl in 
FBS and PPBS. 
4) Mild Improvement: Nominal reduction in 
signs/symptoms, Improvement of <10 mg/dl in FBS 
and PPBS. 
5) Nil / Unchanged: no change in the status of signs or 
symptoms or in the blood glucose levels. 
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OBSERVATIONS AND RESULTS 
A total of 110 patients were registered under the 
trial, out of which 92 patients were completely studied 
upon in the research. Hence, the Observational Data of 
Distribution was presented for 110 patients while Result 
Data of statistical analysis was presented for 92 patients. 
Age wise distribution of patients 
Age: In the Present study maximum (48.18%) patients 
were in the age group of 41-50 yrs which indicates the 
incidence of disease is above 40yrs of age which is in 
concordant with the recent statistical data on the onset 
of type – DM after the age of 40yrs. 
Occupation: Data shows that in present study the 
incidence of Madhumeha is maximum in Housewives 
(31.82%). This occurrence could be because of sedentary 
life-style of most of the house wives and lack of 
awareness on the life-style disorders. 
Family history: Majority of the patients (60%) were 
having positive family history of diabetes. This clearly 
supports the factor of genetic predisposition, an 
important etiology in Type 2 DM. 
Treatment history: In the present study 28.18% of 
patients were using Oral Hypoglycemic Agents (OHA) 
and 23.63% were using Ayurveda treatment while 
32.72% were taking both and 15.45% patients were 
without any treatment. 
This observation confirms that the primary preference of 
general population is usually allopathic management. As 
the awareness of Ayurvedic and other natural healing 
approaches is increasing people are opting these 
modalities after either failing or dissatisfied with the 
allopathic management.  
Chronicity: Chronicity wise distribution of patients 
shows that maximum patients (46.36%) were suffering 
from 1-5 years, while 6.36% had a chronicity of more 
than 10 years. The intractability of the disease directly 
depends on its chronicity and in this study most of the 
subjects are with less chronicity rendering more 
possibility for the research.  
Physical activity: Maximum no. of patients (56.36) were 
leading a sedentary life, indicating a direct etiology to 
Madhumeha. 
Diet pattern: Maximum patients (70%) were 
vegetarians. This criterion is of no significance to the 
study. 
Dominant rasa: Maximum numbers of patients 
(91.82%) have habit of taking Madhura rasa dominant 
diet. This indicates dietary etiology where excessive 
intake of Madhura rasa leads to Kapha and Medo vriddhi, 
thereby Agnimandya, Ama and Kleda utpatti and 
ultimately Margavarodhaja madhumeha.  
Agni: In this study Viṣamagni was observed in majority 
of subjects (37.27%). This indicates the vitiated state of 
Agni leading to improper digestion, assimilation and 
metabolism at organ and cellular level, one of the main 
causes of the disease. 
Sarira prakriti: In 110 patients, maximum (46.36%) 
belongs to Vata- Kaphaja (VK) Prakriti. The main 
pathological factors in Madhumeha being Vata and 
Kapha, this observation confirms the type of body 
constitution responsible for the vulnerability to the 
disease. 
Manasa prakriti: Maximum patients (56.36%) were of 
Rajasa- Tamasa Prakriti. This observation was important 
in the form of temperament laying the foundation for the 
disease. 
Sara: Maximum patients (45.45%) were of Meda-Sara. 
This suggests that Meda sara individuals are more prone 
to Madhumeha. 
Abhyavaharana & Jarana Sakti: In the present study, 
the majority of patients 62.73% had Madhyama 
Abhyavaharana-sakti and maximum patients (56.36%) 
have Madhyama Jaraṇasakti. Though the significance of 
this observation is less it indicates the possibility of 
digestive disturbances leading to Ama formation and 
then to the disease. 
Body weight & BMI: Maximum number of patients 
(33.64%) were having body weight in the range of 61-
70Kg and 4.55% were having >90 Kgs weight and, 
48.18% patients had BMI in between 25-29.9, 40 and 
3.64% patients had BMI >35. These observations though 
are not significant, indicate the direct relation of 
overweight and Madhumeha. 
Nidana sevana: Most of the patients (88.18%) gave the 
history of Ghrita consumption, followed by those who 
consume Ati-snigdha Ahara (82.73%), Milk Products 
(81.82%) Guḍa vaikrita (sugarcane) (80.00%), Ati-Dadhi 
sevana (77.27%), Ati-madhura rasa (73.64%), 
Navannapana (68.18), Ati-sita (60.91), Madhya (Alcohol) 
(35.45) and Mamsa sevana (30.00). 
 According to Viharaja nidana most of the 
patients gave the history of Avyayama (80%), Asyasukha 
(76.36%), Swapnasukha (74.55%), Alasya (69.09%) and 
Divaswapna (33.64%).  
 The diet and life-style aspects in this observation 
highlighted all the factors responsible for the insidious 
development of Madhumeha. 
Rupa: In this study the following symptoms were found 
predominantly: Prabhuta-mutrata (92.73%), Daurbalya 
(78.18%), Avila-mutrata (76.36%), Kaṇṭha-talu- sosa 
(pipasadhikya) (70.00%), Alasya (69.09%) 
Svedatipravritti (68.18%), Kṣudhadhikya (58.18%) and 
Hasta-pada-tala daha (58.18%). 
 The typical symptomatology of Madhumeha is 
observed in more than half of the subjects. Prabhuta 
mutrata (excess and frequent urination) being present in 
almost all the patients indicates the vitiation of Drava 
dhatu, which is also represented by the symptom Avila 
mutrata (turbid urine). Following these are the other 
symptoms like Pipasadhikya, Kantha-talu-sosa, Daurbalya 
etc., which represent the deficiency of proper 
metabolism in the body.  
Upadrava: Most common Upadrava was Neuropathy 
(58.18%) and Daha (58.18) followed by Hypertension 
(50%). Retinopathy was found in 16.36%. Hypoglycemic 
attack and Prameha piḍika have the same incidence i.e. 
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10%. Incidence of Nephropathy was in 6.36% and that of 
gangrene was in 0.09%. 
Altered sensations like polyneuropathy followed by 
burning sensation in peripheries and hypertension were 
observed to be the common complications of 
Madhumeha. The chronic condition of the disease 
resulted in micro-vascular pathologies like retinopathy, 
nephropathy etc. 
RESULTS 
Analysis of Subjective Parameters 
Clinical improvement in Prabhuta-mutrata 
Group N 
Mean 
Diff. % of Change SD SE W P 
BT AT 
A 44 2.21 0.91 1.30 58.95 0.67 0.10 820 <0.0001 (ES) 
B 48 2.18 0.41 1.78 81.31 0.85 0.12 1081 < 0.0001 (ES) 
 
 Mean diff. % of Change 
SD SE U P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 1.30 1.78 58.95 81.31 0.97 0.15 707.5 0.0036 (VS) 
Clinical improvement in Avila mutrata 
Group N 
Mean 
Diff. % of Change SD SE W P 
BT AT 
A 44 1.53 1.19 0.35 22.73 0.92 0.14 285 0.0196 (S) 
B 48 2.12 0.78 1.35 63.46 0.69 0.10 1035 < 0.0001 
(ES) 
Clinical improvement in Naktamutrata 
Group N 
Mean 
Diff. % of Change SD SE W P 
BT AT 
A 44 2.02 0.91 1.12 55.17 0.66 0.10 703 < 0.0001 (ES) 
B 48 2.37 0.53 1.84 77.59 0.80 0.11 1128 < 0.0001 (ES) 
Clinical improvement in Pipasadhikya 
Group N 
Mean 
Diff. % of Change SD SE W P 
BT AT 
A 44 2.02 0.72 1.30 64.37 0.60 0.09 820 < 0.0001 (ES) 
B 48 1.88 0.53 1.35 71.74 0.63 0.09 1128 < 0.0001 (ES) 
Clinical improvement in Swedadhikya 
Group N 
Mean 
Diff. % of Change SD SE W P 
BT AT 
A 44 2.23 1.21 1.02 45.83 0.41 0.06 820 < 0.0001 (ES) 
B 48 2.08 0.67 1.41 67.65 0.73 0.10 1081 < 0.0001 (ES) 
Clinical improvement in Daurbalya 
Group N 
Mean 
Diff. % of Change SD SE W P 
BT AT 
A 44 1.40 1.23 0.16 11.67 0.97 0.15 119 0.2798 (NS) 
B 48 1.41 0.90 0.51 36.23 1.00 0.14 535 0.0014 (VS) 
Group 
Mean diff. % of Change 
SD SE U P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 0.35 1.35 22.73 63.46 1.12 0.17 473.5 < 0.0001 (ES) 
Group 
Mean diff. % of Change 
SD SE U P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 1.12 1.84 55.17 77.59 1.02 0.16 540 < 0.0001 
(ES) 
Group 
Mean diff. % of Change 
SD SE U P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 1.30 1.35 64.37 71.74 0.89 0.14 1043 0.9285 
(NS) 
Group 
Mean diff. % of Change 
SD SE U P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 1.02 1.14 45.83 67.65 0.77 0.12 732.5 0.0024 (VS) 
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Clinical improvement in Ksudhadhikya 
Group N 
Mean 
Diff. 
% of 
Change 
SD SE W P 
BT AT 
A 44 1.53 0.90 0.63 41.33 1.24 0.18 574 < 0.001 (VS) 
B 48 1.60 0.70 0.90 56.52 0.61 0.09 634 < 0.0001 (ES) 
Clinical improvement in Atinidra / Nidradhikya 
Group N 
Mean 
Diff. % of Change SD SE W P 
BT AT 
A 44 1.44 1.02 0.42 29.03 1.01 0.15 321 0.0108 (S) 
B 48 1.33 0.84 0.49 36.92 1.00 0.14 502 0.0019 (VS) 
Clinical improvement in Sramasvasa 
Group N 
Mean 
Diff. % of Change SD SE W P 
BT AT 
A 44 1.16 0.84 0.33 28.00 0.97 0.15 234 0.0348 (S) 
B 48 1.33 0.88 0.45 33.85 1.00 0.14 479 0.0039 (VS) 
Clinical improvement in Mukhamadhurya 
Group N 
Mean 
Diff. % of Change SD SE W P 
BT AT 
A 44 1.53 0.60 0.93 60.61 0.46 0.07 703 < 0.0001 (ES) 
B 48 1.20 0.27 0.94 77.97 0.52 0.07 861 < 0.0001 (ES) 
Clinical improvement in Vibandha 
Group N 
Mean 
Diff. % of Change SD SE W P 
BT AT 
A 44 1.20 0.67 0.53 44.07 1.00 0.14 470 < 0.0011 (VS) 
B 48 1.72 0.77 0.95 55.41 0.72 0.11 528 < 0.0001 (ES) 
Clinical improvement in Hasta-Pada-tala daha 
Group N 
Mean 
Diff. % of Change SD SE W P 
BT AT 
A 44 1.53 0.70 0.83 54.55 0.53 0.08 561 < 0.0001 (ES) 
B 48 1.63 0.31 1.32 81.25 0.83 0.12 861 < 0.0001 (ES) 
 
Group 
Mean diff. % of Change 
SD SE U P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 0.16 0.51 11.67 36.23 1.36 0.21 847 0.0775 (NS) 
Group 
Mean diff. % of Change 
SD SE U P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 0.90 0.63 56.52 41.33 1.46 0.22 986 0.5668 (NS) 
Group 
Mean diff. % of Change 
SD SE U P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 0.42 0.49 29.03 36.92 1.48 0.23 1010 0.7114 (NS) 
Group 
Mean diff. % of Change 
SD SE U P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 0.33 0.45 28.00 33.85 1.31 0.20 969 0.4715 (NS) 
Group 
Mean diff. % of Change 
SD SE U P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 0.93 0.94 60.61 77.97 0.73 0.11 1047 0.9539 (NS) 
Group 
Mean diff. % of Change 
SD SE U P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 0.95 0.53 55.41 44.07 1.39 0.21 812 0.0422 (S) 
Group 
Mean diff. % of Change 
SD SE U P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 0.83 1.32 54.55 81.25 0.96 0.15 691 0.0018 (VS) 
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Clinical improvement in Kara-Pada suptata 
Group N 
Mean 
Diff. % of Change SD SE W P 
BT AT 
A 44 1.42 0.60 0.81 57.38 0.59 0.09 496 < 0.0001 (ES) 
B 48 1.14 0.35 0.80 69.64 0.79 0.11 435 < 0.0001 (ES) 
          
 
Clinical improvement in Pipilika-Sancharati 
Group N 
Mean 
Diff. % of Change SD SE W P 
BT AT 
A 44 1.42 0.58 0.84 59.02 0.57 0.09 528 < 0.0001 (ES) 
B 48 1.45 0.49 0.96 66.20 0.54 0.08 861 < 0.0001 (ES) 
Subjective Parameters
 The effect of therapy on the variable Prabhuta 
mutrata is statistically extremely significant (p<0.0001) 
in both Groups, while clinically Group A showed 58.95% 
relief and Group B showed 81.31% relief. When the two 
Groups A & B were compared the difference was very 
significant (p=0.0036) between the two groups 
indicating a better therapeutic effect in Group B than in 
Group A.  
 In the variable Avila mutrata Group A showed 
22.73% relief with p-value of 0.0196, which was a 
significant result, Group B showed 63.46% relief with p 
value of <0.0001 which was an Extremely significant 
result. When both groups are compared, two tailed p 
value is <0.0001, which is an extremely significant result, 
indicating a better result in Group B than in Group A. 
The effect of therapy on the variable 
Naktamutrata is statistically extremely significant 
(p<0.0001) in both Groups, while clinically Group A 
showed 55.17% relief and Group B showed 77.59% 
relief. When two groups A & B were compared, the 
difference was extremely significant (p<0.0001), 
indicating a better therapeutic effect in Group B than in 
Group A. 
The effect of therapy on the variable 
Pipasadhikya is statistically extremely significant 
(p<0.0001) in both Groups, while clinically Group A 
showed 64.37% relief and Group B showed 71.74% 
relief. When two groups A & B were compared, two tailed 
p value is 0.9285, where the difference is though 
statistically Non-significant, clinically Group B was more 
effective than Group A. 
The effect of therapy on the variable 
Swedadhikya is statistically extremely significant 
(p<0.0001) in both Groups, while Group A showed 
45.83% relief and Group B showed 67.65% relief. When 
the two groups A & B were compared, the two tailed p 
value is 0.0024 where the difference is very significant 
indicating a clinically better result in Group B than in 
Group A. 
In the variable Daurbalya, Group A showed 
11.67% relief with p-value 0.2798 which is not 
significant and Group B showed 36.23% relief with p-
value 0.0014 which is very significant. When the two 
Groups are compared the two tail p value is 0.0775, 
which is though not a significant difference indicates a 
better clinical effect in Group B than in Group A due to 
the % relief. 
In the variable Ksudhadhikya statistically p-value 
is <0.001 in Group A which is Extremely significant and 
p-value is <0.0001 in Group B which is a very significant 
result; Clinically Group B showed 56.52% relief and 
Group A showed 41.33% relief. While both groups are 
compared p=0.5668 which suggests that Clinically Group 
B has a better effect than Group A. 
In the variable Atinidra / Nidradhikya, Group B 
showed 36.92% relief with p-value 0.0019 which was 
very significant result and Group A showed 29.03% relief 
with p-value 0.0108 which was also a significant result. 
When the two groups A & B were compared, there was 
no significant difference (p=0.7114) between the two 
groups which implies that clinically Group B is better 
than Group A. 
In the variable Sramasvasa, Group B showed 
33.85% relief with p-value 0.0039, which was very 
significant result and Group A showed 28.00% relief with 
p-value 0.0348 which was also a significant result. When 
the two groups A & B were compared, there was no 
significant difference (p=0.4715) between the two 
groups, which implies that clinically Group B is better 
than Group A. 
The effect of therapy on the variable 
Mukhamadhurya is statistically extremely significant 
(p<0.0001) in both Groups, while clinically Group B 
showed 77.97% relief and Group A showed 60.60% 
relief. When the two groups A & B were compared, there 
was no significant difference (p=0.9539) between the 
groups suggesting that clinically Group B yielded better 
result than Group A. 
Group 
Mean diff. % of Change 
SD SE U P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 0.81 0.80 57.38 69.64 1.11 0.17 1001 0.6537 (NS) 
Group 
Mean diff. % of Change 
SD SE U P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 0.84 0.96 59.02 66.20 0.80 0.12 942 0.2882 (NS) 
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In the variable Vibandha, Group B showed 
55.41% relief with p-value < 0.0001, which was an 
Extremely significant result and Group A showed 44.07% 
relief with p-value< 0.0011 which was a very significant 
result.  When the two groups A & B were compared, the 
difference was significant (p=0.0422) suggesting that 
clinically Group B has a better effect than Group A. 
 The effect of therapy on the variable Hasta-Pada-
tala is statistically extremely significant (p<0.0001) in 
both Groups, while Group A showed 54.55% relief and 
Group B showed 81.25% relief. When both the groups 
are compared the p value is 0.0018 indicating a very 
significant difference suggesting that clinically Group B 
has a better effect than Group A. 
The effect of therapy on the variable Kara-Pada 
suptata is statistically extremely significant (p<0.0001) 
in both Groups, while Group A showed 57.38% relief and 
Group B showed 69.64% relief. When the two groups A & 
B were compared, there was no significant difference 
(p=0.6537) between the groups, suggesting clinically 
more efficacy in Group B than in Group A. 
The effect of therapy on the variable Pipilika-
Sancharati is statistically extremely significant 
(p<0.0001) in both Groups, while Group B showed 
66.20% relief and Group A showed 59.02% relief. When 
the two groups A & B were compared, there was no 
significant difference (p=0.2882), suggesting clinically 
more efficacy in Group B than in Group A. 
ANALYSIS OF OBJECTIVE PARAMETERS 
Pattern of improvement in FBS 
Group N 
Mean 
Diff. % of Change SD SE t P 
BT AT 
A 44 191.43 131.27 60.16 31.43 36.52 5.22 11.53 < 0.0001 (ES) 
B 48 195.37 130.79 64.58 33.05 31.30 4.77 13.53 < 0.0001 (ES) 
Pattern of improvement in PPBS 
Group N 
Mean 
Diff. 
% of 
Change 
SD SE t P 
BT AT 
A 44 269.53 193.00 76.53 28.39 41.53 6.33 12.08 < 0.0001 (ES) 
B 48 265.69 189.71 75.98 28.60 45.65 6.52 11.65 < 0.0001 (ES) 
Pattern of improvement in GHb (HbA1C) 
Group N 
Mean 
Diff. % of Change SD SE t P 
BT AT 
A 44 7.75 6.62 1.13 14.55 0.68 0.10 10.82 < 0.0001 (ES) 
B 48 7.42 6.27 1.14 15.43 0.89 0.13 9.05 < 0.0001 (ES) 
Pattern of improvement in Se. Cholesterol 
Group N 
Mean 
Diff. 
% of 
Change 
SD SE t P 
BT AT 
A 44 206.49 183.35 23.14 11.21 23.90 3.64 6.35 < 0.0001 (ES) 
B 48 219.40 179.43 39.97 18.22 27.30 3.90 10.25 < 0.0001 (ES) 
Pattern of improvement in Se. Triglycerides 
Group N 
Mean 
Diff. 
% of 
Change 
SD SE t P 
BT AT 
A 44 182.37 159.23 23.14 12.69 30.30 4.62 5.01 < 0.0001 (ES) 
B 48 190.08 151.69 38.39 20.20 29.76 4.25 9.03 < 0.0001 (ES) 
Group 
Mean diff.  % of Change 
SD SE t P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 60.16 64.58 31.43 33.05 59.01 9.00 0.49 0.5380 (NS) 
Group 
Mean diff. % of Change 
SD SE t P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 76.53 75.98 28.39 28.60 70.52 10.75 0.05 0.9525 (NS) 
Group 
Mean diff. % of Change 
SD SE t P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 1.13 1.14 14.55 15.43 1.26 0.19 0.09 0.9191 (NS) 
Group 
Mean diff. % of Change 
SD SE t P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 23.14 39.97 11.21 18.22 36.76 5.61 3.51 0.0024 (VS) 
Group 
Mean diff. % of Change 
SD SE t P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 23.14 38.39 12.69 20.20 36.72 5.60 3.23 0.0170 (S) 
 K.V.Narasimha Raju, Radhey Shyam Sharma. Study of Vamana & Virechana with and without Shilajit Yoga in the Management 
of Madhumeha w.s.r. to Type-2 Diabetes Mellitus 
AYUSHDHARA | July - August 2016 | Vol 3 | Issue 4  758 
Pattern of improvement in Se. HDL Cholesterol 
Group N 
Mean 
Diff. % of Change SD SE t P 
BT AT 
A 44 59.88 59.56 0.33 0.54 7.37 1.12 0.29 0.7735 (NS) 
B 48 60.16 57.78 2.38 3.96 7.04 1.01 2.37 0.0220 (S) 
Pattern of improvement in Se. LDL Cholesterol 
Group N 
Mean 
Diff. 
% of 
Change 
SD SE t P 
BT AT 
A 44 109.86 92.61 17.25 15.70 19.96 3.04 5.67 <0.0001 (ES) 
B 48 121.61 89.24 32.37 26.61 27.25 3.89 8.31 <0.0001 (ES) 
Showing pattern of improvement in Se. VLDL 
Group N 
Mean 
Diff. 
% of 
Change 
SD SE t P 
BT AT 
A 44 36.20 31.72 4.48 12.38 6.78 1.03 4.34 <0.0001 (ES) 
B 48 37.85 29.82 8.03 21.22 6.69 0.96 8.40 <0.0001 (ES) 
Pattern of improvement in Specific Gravity 
Group N 
Mean 
Diff. 
% of 
Change 
SD SE t P 
BT AT 
A 44 1.03 1.02 0.01 0.56 0.01 0.001 5.54 0.0003 (ES) 
B 48 1.03 1.02 0.01 0.86 0.005 0.0007 12.63 <0.0001 (ES) 
Pattern of improvement in FUS (Fasting Urine Sugar) 
Group N 
Mean 
Diff. % of Change SD SE t P 
BT AT 
A 44 2.55 0.94 1.61 63.13 0.79 0.11 14.36 <0.0001 (ES) 
B 48 2.12 0.67 1.45 68.39 0.59 0.09 16.03 <0.0001 (ES) 
Pattern of improvement in Body weight 
Group N 
Mean 
Diff. 
% of 
Change 
SD SE t P 
BT AT 
A 44 70.55 69.29 1.27 1.79 1.09 0.16 8.09 <0.0001 (ES) 
B 48 69.37 66.56 2.81 4.06 0.70 0.11 26.40 <0.0001 (ES) 
Pattern of improvement in BMI (Body mass Index) 
Group N 
Mean 
Diff. 
% of 
Change 
SD SE t P 
BT AT 
A 44 25.59 25.19 0.40 1.57 0.98 0.14 2.86 0.0062 (VS) 
B 48 26.41 25.34 1.07 4.06 0.26 0.04 26.80 <0.0001 (ES) 
Group 
Mean diff. % of Change 
SD SE t P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 0.33 2.38 0.54 3.96 8.46 1.29 1.59 0.1753 (NS) 
Group 
Mean diff. % of Change 
SD SE t P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 17.25 32.37 15.70 26.61 35.64 5.43 3.17 0.0035 (VS) 
Group 
Mean diff. % of Change 
SD SE t P 
Grp. A Grp. B Grp. A  Grp. B 
A vs B 4.48 8.03 12.38 21.22 8.31 1.27 2.80 0.0134 (S) 
Group 
Mean diff. % of Change 
SD SE t P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 0.01 0.01 0.56 0.86 0.01 0.001 2.96 0.0695 (NS) 
Group 
Mean diff. % of Change 
SD SE t P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 1.61 1.45 63.20 68.13 1.11 0.17 2.05 0.2479 (NS) 
Group 
Mean diff. % of Change 
SD SE t P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 1.27 2.81 1.79 4.06 1.62 0.25 6.27 <0.0001 (ES) 
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Overall comparison of effect of the therapy in 92 patients of Madhumeha 
S. No. Total effect of therapy 
Group-A (N= 44) Group-B (N= 48) Total (N= 92) 
No. of Pts. % No. of Pts. % No. of Pts. % 
1 Controlled  6 13.63% 24 50% 30 32.60% 
2 Marked Improvement 10 22.72% 14 29.1% 24 26.08% 
3 Moderate Improvement 24 54.54% 10 20.8% 34 36.95% 
4 Nil / Unchanged  4 9.0% 0 0% 4 4.34% 
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Mean diff. % of Change 
SD SE t P 
Grp. A Grp. B Grp. A Grp. B 
A vs B 0.40 1.07 1.57 4.06 1.04 0.16 4.21 <0.0001 (ES) 
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 The effect of therapy on Fasting Blood Sugar is 
statistically extremely significant (p<0.0001) in both 
Group A & B. On comparison between the groups, though 
the difference is not statistically significant (p=0.5380), 
clinically Group B with 33.05% change was more 
effective in reducing Fasting Blood sugar than Group A 
with 31.43% change. 
The effect of therapy on PPBS is statistically 
extremely significant (p<0.0001) in Both Groups A & B. 
On comparison between the groups though the 
difference is not statistically significant (p=0.9525), 
clinically Group B with 28.60% change was more 
effective in reducing Post Prandial Blood Sugar than 
Group A with 28.39% change. 
The effect of therapy on Glycosylated 
Haemoglobin (GHb/HbA1C) is statistically extremely 
significant (p<0.0001) in Both Group A & B. On 
comparison between the groups though the difference is 
not statistically significant (p= 0.9191), clinically Group B 
with 15.43% change was more effective on Glycosylated 
haemoglobin than Group A with 14.55% change. 
The effect of therapy on Se. Cholesterol is 
statistically extremely significant (p<0.0001) in both 
Group A & B. Inter group comparison showed very 
significant difference (p=0.0024) between two groups 
suggesting that clinically Group B (18.22%) was more 
effective than Group A (11.21%).  
The effect of therapy on Se. Triglyceride is 
statistically extremely significant (p<0.0001) in Group A 
& B. Intergroup comparison showed significant 
difference (p=0.017) between two groups suggesting 
that clinically Group B (20.20%) was more effective than 
Group A (12.60%). 
In the variable Se. HDL Cholesterol, Group B 
showed 3.96% of change with p-value 0.0220 which is 
statistically significant and Group A showed 0.54% of 
change with p-value 0.7735 which is not a significant 
result. Inter group comparison yielded non- significant 
(p=0.1753) difference, conferring that clinically Group B 
was more effective than group A. 
 The effect of therapy on Se. LDL was extremely 
significant (p<0.0001) in Group A & B. When the two 
groups were compared, there was very significant 
difference (p=0.0035) between two groups indicating 
that clinically Group B was more effective with a change 
of 26.61% than Group A with 15.70% change. 
 The effect of therapy on Serum VLDL Cholesterol 
was statistically extremely significant (p<0.0001) in 
Group A & B. When the two groups were compared, there 
was significant difference (p=0.013) between the groups 
indicating that clinically Group B with 21.22 % change 
was more effective than Group A with 12.38 % change. 
The effect of therapy in urine Specific Gravity is 
statistically extremely significant with p-values 0.0003 & 
<0.0001 in Group A & B respectively. When the Groups A 
& B were compared, there is no significant difference 
(p=0.0695) between Groups, suggesting that clinically 
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Group B with 0.86% change was more effective than 
Group A with 0.56% change. 
The effect of therapy in FUS (Fasting Urine 
Sugar) is statistically extremely significant with p-values 
<0.0001 in both Group A & B. Inter group comparison 
showed no significant difference (p=0.2479) between the 
groups indicating that clinically Group B showed better 
effect with 68.13% of change than Group A with 63.20% 
of change.  
In minimizing body weight both the Groups A & 
B were extremely significant with p-value <0.0001 and 
the inter-group comparison showed extremely 
significant difference in between the groups indicating 
that clinically Group B was very effective with a change 
of 4.06% when compared to 1.79% in Group A. 
In BMI, Statistical evaluation of studied groups 
showed extremely significant (P<0.0001) result in Group 
B and very significant (p=0.0062) result in Group A. The 
inter-group comparison showed extremely significant 
difference (p<0.0001) in between group A & B and 
clinically Group B with 4.06% of change was more 
effective than Group A with 1.57% of change. 
Over all comparison of effect of therapy 
In case of placebo controlled Group-A, 6 patients 
(13.63%) got Controlled results, 10 (22.72%) patients 
got Marked Improvement, 24 (54.54%) patients got 
Moderate Improvement, 4 (9%) patients got Mild 
Improvement and in 4 patients there is No Change at the 
end of the study.  
In case of Drug trial (Shilajit Yoga) Group-B, 24 
(50%) patients got Controlled results, 14 (29.1%) 
patients got Marked Improvement and 10 (20.8%) 
patients got Moderate Improvement. 
DISCUSSION ON PHARMACO- KINETICS: 
 Type‑2 diabetes occurs due to impaired insulin 
secretion, peripheral Insulin Resistance and 
Excessive Hepatic Glucose production. Insulin 
resistance impairs glucose utilization by insulin 
sensitive tissues and increase hepatic glucose 
output, both these effects contribute to the 
hyperglycemia.  
 Increased hepatic glucose output predominantly 
accounts for increased fasting hyperglycemia, 
whereas decreased peripheral glucose uptake 
results in postprandial hyperglycemia [8]. 
 Bahudravasleshma and Bahuabaddhameda [9] are 
the basic pathological factors for Prameha. 
Bahudravasleshma could be because of tissue 
defect, whereas Bahu‑abaddhameda can be 
correlated with free fatty acids, which are released 
from intra abdominal central adipose tissues. Free 
fatty acid is the main etio-pathological factor for 
Insulin Resistance.  
 Also, the derangement of glucose, fat and protein 
metabolism during Diabetes results in the 
development of hyperlipidaemia [10] [11] [12]. 
 As far as Vamana is concerned it alleviates primarily 
Kapha and to some extent Pitta. Here Vamana seems 
to reduce the peripheral insulin resistance in 
muscles by alleviating Bahudravasleshma and so 
helping to increase the glucose uptake. As Vamana 
also reduces the Meda, it must be promoting the 
function of insulin by reducing the circulating free 
fatty acids in the body. 
  As the effect of Virechana is at the site of Pitta it 
can be hypothesized that by acting primarily on liver and 
pancreas it may help to reduce hepatic glucose 
production and increase insulin production by 
overcoming the impaired insulin secretion condition.  
Both of these procedures justify their role in 
reducing both FBS and PPBS considerably. Vamana acts 
on the basic pathology of Bahudravasleshma and 
Bahuabadhameda. It is clear that both Vamana and 
Virechana are reducing the insulin resistance and 
Virechana must be increasing insulin secretion also.  
 There were some patients in both groups who could 
maintain their FBS and PPBS well in control even 
during the follow up with the antidiabetic diet 
regimen and life style changes. However, this trend 
could not be maintained for long where increase in 
both FBS and PPBS was noted, suggesting the fact 
that only Vamana or Virechana is not capable enough 
to maintain the sugar levels.  
Prameha is an Anushangivyadhi - disease having 
relapsing nature. Hence, for better control of blood sugar 
levels, along with this Shodana therapy Rasayana chikitsa 
(rejuvenation therapy) is needed.  
DISCUSSION ON MODE OF ACTION 
In Prameha, the predominant Dosha (causative 
factors) and Dushya (effected tissue) are Kapha and Meda 
(fat). Panchakola churna selected for Deepana‑paachana 
increases Agni and alleviates Kapha and Meda. Its 
indication in Prameha is probably due to its therapeutic 
effect in breaking the pathogenesis of Prameha.  
Ghrita (ghee) has been mentioned as best Sneha 
in Ayurveda because of its specific qualities of 
Yogavahitva (substance which acquires the property of 
another substance when combined together and acts as 
catalyst) and Samsakaranuvartana (property to 
assimilate effectively the properties of other substances). 
Hence, Ghrita was chosen for Abhyantara snehana 
purpose. (It may help to reduce the insulin resistance at 
cellular level as well as the circulating free fatty acids in 
the blood).  
Apart from Kapha and Medas for which Vamana 
karma is advised, Patients with Madhumeha (DM) 
commonly have the condition of Malabaddhata and Pitta 
participation, in whom Virechana karma will be of 
substantial use.  
 Hence, It can be inferred that both Vamana and 
Virechana cause marked reduction in FBS and PPBS 
levels. In early course of disease Samshodhana must be 
the choice of treatment; as at this stage, patient has 
dominance of Kapha and Pitta. 
It can be hypothesized that Vamana- by reducing 
Kapha and Meda helps to minimize insulin resistance, 
whereas Virechana- probably by lowering down the 
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hepatic glucose production and probably by promoting 
insulin secretion helps to control blood sugar. 
Nevertheless, as Prameha is Anushangivyadhi, neither 
Vamana nor Virechana alone can act as complete 
treatment for it. Hence, in the present study the DM-II 
patients in both the Groups were first subjected to 
Shodhana karma (which included both Vamana karma 
and Virechana karma) followed by conservative therapy, 
wherein Group B was intervened with Shilajit Yog and 
Group A with Placebo.  
Shilajit considered for the present study was 
processed and potentiated through 7 Bhavanas with 
Salasaradi gana dravya kashaya. The processed and 
powdered Shilajit is dispensed to patients (Gr-B) in 
Capsule (1000mg capacity) form to be consumed twice in 
a day before food with Salasaradi gana kashaya as 
Anupana. 
The Organoleptic properties of Shilajit in 
Ayurvedic terms are Anamlam, Katu- Tikta- Kashaya- 
rasa, Soshana-Chedana guna, Ushna virya and Katu 
vipaka. Researches revealed that Shilajit, along with extra 
pancreatic, immunomodulatory[13] and antioxidant 
effects [14][15] increases the number of β-cells of pancreas, 
i.e. pancreatotrophic action, which may result in better 
sensitivity of pancreatic β- cells with prompt secretion of 
a large quantity of insulin in response to hyperglycemia 
[16]. Along with proved anti-diabetic activity [17] [14] Shilajit 
is also clinically tested for its anti-hyperlipidaemic 
activity [18].  
In Salasaradi gana there are 23 drugs out of 
which 6 drugs viz., Khadira, Kramuka, Meshasringi, 
Sirisha, Arjuna and Karanja were procured as per the 
availability in the market. The organoleptic properties of 
all these drugs consists of Katu- Tikta- Kashaya- rasa, 
Laghu-Ruksha guna, Katu vipaka and have the 
pharmacotherapeutic effects of Kapha-Pitta samana and 
Prameha hara.  
Out of the 6 drugs- Khadira, Kramuka, Arjuna 
shows Sita virya and Meshasringi, Sirisha, Karanja shows 
Ushna virya. In addition to the Pramehahara property 
Khadira possess Medohara property and Sirisha posses 
Sothahara property. The scientific studies of these drugs 
revealed potential Anti-Hyperglycemic and Anti-
Hyperlipidaemic properties in alloxan and streptozotocin 
induced diabetic rats. These 6 drugs were used for the 
preparation of Kashaya to be used as Bhavana dravya for 
Shilajit and the same drugs were dispensed to the 
patients in coarse powder form for preparing Kashaya to 
be used as Anupana to Shilajit yog capsules. The 
cumulative effect of all these properties must have 
resulted in Samprapti vighatana of Madhumeha vyadhi. 
In contrast to Group A (placebo), Salasaradi 
gana dravya bhavita Shilajit- ‘Shilajit yoga’ intervened in 
Group B appears to have substantial controlling effect on 
the blood sugar levels, following Shodhana karma 
through Vamana and Virechana.  
 
 
CONCLUSION 
 Both Vamana and Virechana justify their role in 
reducing both FBS and PPBS considerably. Vamana 
acts on the basic pathology of Bahudravasleshma and 
Bahuabadhameda. Vamana and Virechana are 
reducing the insulin resistance and Virechana must 
be increasing insulin secretion also.  
 Prameha is an Anushangivyadhi - disease having 
relapsing nature. Hence, for better control of blood 
sugar levels, along with this Shodana therapy 
Rasayana chikitsa (rejuvenation therapy) is 
administered.  
 Both the Groups were first subjected to Shodhana 
karma (which included both Vamana karma and 
Virechana karma) followed by conservative therapy, 
wherein Group B was intervened with Shilajit Yog 
and Group A with Placebo.  
In contrast to Group A, Salasaradi gana dravya 
bhavita Shilajit- ‘Shilajit yoga’ intervened in Group B 
appears to have substantial controlling effect on the 
blood sugar levels with its Extra pancreatic and 
Immunomodulatory effects, and probably through 
Pancreatotrophic action. The final result of the study 
supports the role of Shilajit followed by Shodana 
procedures as substitute for the allopathic medication in 
the patients with an excess of about 50-100mg/dl of 
blood glucose levels above normal levels, in FBS and 
PPBS values.   
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